- Home
- PTLO vs ADAG Comparison
PTLO vs ADAG Comparison
Compare PTLO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTLO | ADAG |
|---|---|---|
| Founded | 1963 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.3M | 260.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PTLO | ADAG |
|---|---|---|
| Price | $4.76 | $4.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $8.06 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 1.3M | 288.1K |
| Earning Date | 05-05-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $732,066,000.00 | N/A |
| Revenue This Year | $9.02 | N/A |
| Revenue Next Year | $5.81 | N/A |
| P/E Ratio | $54.56 | ★ N/A |
| Revenue Growth | ★ 3.03 | N/A |
| 52 Week Low | $3.78 | $1.44 |
| 52 Week High | $7.34 | $4.85 |
Technical Indicators
Market Signals| Indicator | PTLO | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 57.67 |
| Support Level | $4.41 | $3.23 |
| Resistance Level | $4.94 | $4.41 |
| Average True Range (ATR) | 0.25 | 0.30 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 52.68 | 67.95 |
Price Performance
Historical ComparisonAbout PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. The company owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, sides and soup, and others.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.